Balkan Journal of Medical Genetics

A NEW CLOCK IS RUNNING FOR MULTIPLE MYELOMA: CIRCADIAN CLOCK PROTEIN-PERIOD 3 (PER-3) POLYMORPHISM
Serin I.1,*, Pehlivan S.2, Demir I.3, Oyacı Y.2, Pehlivan M.3
*Corresponding Author: Istemi Serin, M.D., University of Health Sciences, Istanbul Training and Research Hospital, Department of Hematology, Org. Nafiz GURMAN Cad., Fatih, 34098 tel.: +90 532 3172393, e-mail: serinistemi@hotmail.com
page: 37

MATERIAL AND METHODS

One hundred fifty patients (over 18 years old), diagnosed with MM in Hematology Clinic of Gaziantep University between January 2007 - 2009, and 100 healthy persons were included in this study. Demographic characteristics, first-line treatments, clinical scores (Durie-Salmon stages, ISS score, Eastern Cooperative Oncology Group (ECOG) score), laboratory variables, status of survival (overall (OS) and progression-free (PFS)) were recorded. All patients were suitable for ASCT at first evaluation and following four courses on bortezomib-cyclophosphamide and dexamethasone (VCD) at partial remission (PR), ASCT was carried out. Following 24 months, lenalidomide- dexamethasone (LD) was used as maintenance. The genotypes of 4R/4R-5R, 5R/5R and alleles of 4R and 5R on PER-3 gene of patients with ASCT and healthy controls; were statistically compared before treatment. In addition, these genotypes, the effects of on PFS and OS were investigated. Study approval was obtained from Gaziantep University Ethics Committee (07-2007/40). Isolation Method DNA isolation via peripheral blood leukocytes was measured by the saline precipitation method [10]. Genotypes of PER-3 gene polymorphism were studied by polymerase chain reaction- (PCR) and agarose gel electrophoresis method [11]. Statistical Analysis According to the Kolmogorov-Smirnov test, quantitative variables that fit the normal distribution were shown as mean±standard deviation, but those that did not fit were shown as median (minimum and maximum). Comparisons between qualitative measures expressed as numbers and percentages (%) were made using Chi-square or Fisher’s exact tests. Post-hoc analysis was evaluated with Bonferroni correction for intergroup comparisons. Variables associated with different gene variants were determined in the multivariate logistic regression model adjusted for gender and age. Regression results are shown with odds ratio (OR) and 95% confidence interval (CI). Hardy Weinberg Equilibrium (HWE) was performed via the De-Finetti program (online HWE and Association Testing- Institut für Humangenetik, Munich, Germany). All analyses were performed with IBM SPSS version v21.0 (IBM Corp, Armonk, NY, USA), and a p-value less than 0.05 was considered statistically significant.

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact